. 2017 May 30;177(2):195–205. doi: 10.1530/EJE-16-0905
This work is licensed under a Table 3.
Patients baseline characteristics and conditions in the phase III study (FAS). Data are presented as mean ± s.d. or as n (%).
| PEG-rhGH 0.2 mg/kg/week (n = 228) | Daily rhGH 0.25 mg/kg/week (n = 115) | P value | |
|---|---|---|---|
| n | 228 | 115 | |
| Chronological age (year) | 11.30 ± 3.50 | 11.77 ± 3.60 | 0.2465b |
| Sex, n (%) | 0.7958a | ||
| Male | 187 (82.02) | 93 (80.87) | |
| Female | 41 (17.98) | 22 (19.13) | |
| Weight (kg) | 23.22 ± 6.41 | 24.73 ± 7.91 | 0.0777b |
| Height (cm) | 116.33 ± 12.74 | 119.16 ± 12.55 | 0.0548b |
| MPH (cm) | 166.71 ± 6.93 | 166.42 ± 6.40 | 0.7101b |
| BA (year) | |||
| Male | 7.27 ± 2.09 | 7.49 ± 2.04 | 0.4199b |
| Female | 5.15 ± 2.23 | 6.38 ± 2.52 | 0.0501b |
| BA/CA | 0.62 ± 0.13 | 0.63 ± 0.13 | 0.6491b |
| HV (cm/year) | 2.3 ± 0.9 | 2.3 ± 0.8 | 0.9277b |
| IGF1 SDS | −1.86 ± 1.08 | −1.74 ± 1.08 | 0.3381b |
| HTSDS | −4.52 ± 2.02 | −4.46 ± 1.89 | 0.7676b |
| Corrected HTSDS | −4.18 ± 2.24 | −4.06 ± 2.06 | 0.6302b |
| Pituitary gland MRI, n (%) | 0.9662a | ||
| Normal | 124 (56.88) | 64 (56.64) | |
| Abnormalc | 94 (43.12) | 49 (43.36) | |
| GH peak concentration (μg/L) | 2.55 ± 2.34 | 2.41 ± 2.38 | 0.596b |
| IGHD/MPHD | 216/12 | 108/7 | 0.771b |
a
Differences between the two groups were assessed using bidirectional disorder CMH-χ2 or Fisher’s exact probability test. bDifferences between the two groups were assessed using the t-test. cPituitary hypoplasia.
BA, bone age; BA/CA, bone age/chronological age; HTSDS, height standard deviation score; HV, height velocity; IGF1, insulin-like growth factor-1; IGHD, isolated growth hormone deficiency; MPH, mid-parental height; MPHD, multiple pituitary hormone deficiencies; MRI, magnetic resonance imaging.